BioGenCell
Netanya, Israel· Est.
Israeli cell‑therapy pioneer developing autologous blood‑derived treatments for microvascular and broader regenerative diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli cell‑therapy pioneer developing autologous blood‑derived treatments for microvascular and broader regenerative diseases.
VascularCardiovascularNeurologyOncologyImmunologyRegenerative Medicine
Technology Platform
TRACT is an autologous blood‑derived cell‑therapy platform that isolates, activates, and formulates patient‑specific stem‑cell and immune components for point‑of‑care administration.
Opportunities
Successful Phase 2 data could unlock rapid expansion into cardiac, neuro‑vascular and oncology indications, attracting strategic partnerships or acquisition interest.
Risk Factors
Regulatory approval for autologous cellular therapies and scaling manufacturing while maintaining product consistency remain significant challenges.
Competitive Landscape
BioGenCell competes with allogeneic cell‑therapy firms and device‑based PAD treatments, differentiating through an autologous, point‑of‑care platform that promises lower immunogenicity and cost.